SpectraCure AB Quarterly report (1 April to 30 June) 2019
Second quarter (1 April – 30 June 2019) Net sales for the quarter amounted to TSEK 0 (0). Other income amounted to TSEK 663 (406). Profit after tax amounted to TSEK -4 149 (-4 028). Corresponding to SEK -0,05 (-0,07) per share. Operating cash flow was TSEK -3 547 (-2 977). Cash as of 30 […]
SpectraCures new generation P18
SpectraCure’s current main focus are the clinical phase 2 study and the development of the new generation of SpectraCure's treatment system. The clinical trial, designated for treatment of patients with recurrent prostate cancer using the company's photodynamic therapy (PDT) technology, is ongoing at our partner hospitals. The recruitment of patients for the fall in the […]
Great attention for SpectraCure in Boston
SpectraCure received a lot of attention around its clinical study results at the World Conference in Boston, attended by world leading clinical researchers. On Wednesday, July 3rd, SpectraCure presented results from the company's phase 1 study at the 17th International Photodynamic Association World Congress in Boston, USA. Johannes Swartling, CTO of SpectraCure held the presentation […]
SpectraCure reports positive results from the company’s clinical phase 1-study
Today July 2nd, 2019, SpectraCure AB ("Spec") reports positive results and good clinical effects regarding safety in the company's clinical phase 1-study of patients with recurrent prostate cancer. SpectraCure has conducted a clinical phase 1-study on treatment of patients with recurrent prostate cancer with the company's photodynamic therapy (PDT) technology. A total of 11 patients […]
SpectraCure presents results from Phase 1 study
SpectraCure presents results from the company's Phase 1 study at The 17th International Photodynamic Association World Congress in Boston. SpectraCure (publ) will present results from the company's Phase 1 study at the International Photodynamic Association World Congress arranged June 28th – July 4th in Boston, Massachusetts, USA. The presentation will be held by Johannes Swartling, […]
Preliminary results from SpectraCure’s prostate treatments
Preliminary results have been reported from the latest patient treatments in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital. A very clear treatment effect is seen on MR images in the treatment area, indicating destruction of the tumour, just like previously treated patients with the high […]
New patient treatment, phase 2 initiated
A patient was treated on Tuesday April 9th, 2019, in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital. The treatment was performed with SpectraCure's photodynamic therapy (PDT) method. The procedure went as expected and the patient is doing well. "It is gratifying that we are now […]
SpectraCure files for a new patent
SpectraCure has filed for a new patent to the European Patent Office, the patent covers a new technology to improve the company's IDOSE technology. The IDOSE technique is at the heart of the company's method of treating prostate cancer with photodynamic therapy (PDT). In short, the technique implies that the prostate tissue is monitored during […]
Status report for phase 2 study
SpectraCure has conducted a Phase 1 clinical trial for the treatment of patients with recurrent prostate cancer with the company's technology for photodynamic therapy (PDT). As previously announced, at the end of 2018, the company entered the final stage of planning for a subsequent phase 2 study. In early 2019, SpectraCure renewed certain contracts and […]
Final preparation for Phase 2 – SpectraCure extends contract with hospital in London
Prior to the upcoming Phase 2 study, SpectraCure has today extended the agreement with University College London Hospital (UCL) for two years. The agreement is intended to cover the entire phase 2 for treatment of patients with recurrent prostate cancer, using the company's photodynamic therapy (PDT) method. The purpose of the Phase 2 study is […]
